Ignite Creation Date:
2024-05-06 @ 1:12 AM
Last Modification Date:
2024-10-26 @ 11:00 AM
Study NCT ID:
NCT01752920
Status:
COMPLETED
Last Update Posted:
2023-06-05
First Post:
2012-12-14
Brief Title:
Phase 12 Study of Derazantinib ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Sponsor:
Basilea Pharmaceutica
Organization:
Basilea Pharmaceutica
Organization Data
Organization:
Basilea Pharmaceutica
Class:
INDUSTRY
Study ID:
ARQ 087-101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Basilea Pharmaceutica
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| ArQule Inc a subsidiary of Merck Sharp Dohme LLC a subsidiary of Merck Co Inc Rahway NJ USA | INDUSTRY |